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Abstract Frontal temporal dementia and Parkinsonism linked
to chromosome 17 (FTDP-17) is caused by splice site and
missense mutations in the tau gene, and characterized by the
accumulation of filamentous tau in cerebral neurons and glia.
The missense mutations reduce the ability of tau to promote
microtubule assembly and increase the ability of tau to form
filaments. In this report we demonstrate that mutants V337M
and R406W are less susceptible than mutant P301L or
corresponding wild type tau to degradation by calpain I. The
differences were at least in part due to changes in accessibility of
a cleavage site located about 100 amino acids off the carboxy-
terminus. The results suggest that the pathogenesis of some
forms of FTDP-17 may involve tau accumulation due to
decreased proteolytic degradation.
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1. Introduction
Frontal temporal dementia with Parkinsonism linked to
chromosome 17 (FTDP-17) is characterized clinically by be-
havioral, cognitive and motor disturbances, and histopatho-
logically by neuronal and glial inclusions which contain in-
soluble forms of the microtubule associated protein tau [1].
Genetic analyses reveal that the disorder is caused by mis-
sense, splice site or deletion mutations in the tau gene [2^6].
Intronic mutations have been located close to the 5P splice site
of exon 10 (+3, +13, +14 and +16) and missense mutations in
exons 9^13. A single deletion of residue K280 has been found
in exon 10. The exon 10 splice site mutations and the exonic
mutations at N279K, L284L and S305N have been shown to
a¡ect the expression of di¡erent tau isoforms, resulting in an
increase of the ratio of tau containing four versus three tan-
dem repeats (3R) in its microtubule binding domain [2^10].
Most of the missense mutations (e.g. P301L, P301S, V337M
and R406W) were shown by in vitro assays to reduce the
ability of tau to bind microtubules and to promote microtu-
bule assembly [8,11,12]. The extent of reduction varied de-
pending on the site and the nature of the mutation. Mutations
also a¡ected the ability of tau to form ¢lamentous structures
through self-interactions [13^15]. Among the FTDP-17 tau
mutants studied, P301L and P301S displayed the highest po-
tential to form ¢laments. Studies of microtubule and tau ¢l-
ament assembly clearly demonstrated that FTDP-17 muta-
tions have a dual e¡ect, suggesting that the pathogenesis of
FTDP-17, which results in the formation of ¢lamentous tau
inclusions, involves at least two mechanisms. Assembly of tau
¢laments as revealed by in vitro studies is a process that
requires the presence of a critical concentration of tau and
includes both a nucleation and an elongation phase [16].
The cellular concentration of tau could be elevated by an
increase in the synthesis of tau or a decrease in the degrada-
tion of tau proteins, or both. The turnover of tau may also be
a¡ected by mutations. The latter issue was addressed in the
present study using calpain I, which is a calcium activated
neutral protease rich in neurons and capable of degrading
tau [17]
2. Materials and methods
2.1. Antibodies
Six rabbit polyclonal (E1, E2, WKS44, E9, WKS45, WKS46) and
two mouse monoclonal (Tau-1, Tau46) anti-tau antibodies were em-
ployed. The epitopes recognized by these antibodies were mapped to
amino acid residues 19^33, 44^55, 162^176, 192^199, 226^240, 258^
266, 358^370, and 420^436 [18,19], respectively. Tau-1 [20] was gen-
erously provided by Dr. L. Binder (Northwestern University) and
Tau46 by Dr. V.M.-Y. Lee (University of Pennsylvania). All polyclo-
nal antibodies were generated in our laboratory and used at 1:500
dilution. Tau-1 was hybridoma supernatant and used at 1:5 and 1:10
dilutions. Tau46 was ascites £uid used at 1:1000 dilution.
2.2. Generation of constructs and mutagenesis
The cDNA for four repeat wild type tau (4R, +2 +3, or T40) was
initially provided by Dr. M. Goedert (MRC, Cambridge). Utilizing
the pRK172 construct, a three repeat sibling cDNA was created as
follows. Using the BclI and S¢I sites, the fragment of DNA contain-
ing exon 10 was removed and replaced with the same digestion frag-
ment from a pBS tau clone lacking exon 10. Mutagenesis was per-
formed according to the manufacturer’s instructions. The sequences of
mutagenesis oligos for generation of mutants [4R: P301L, V337M and
R406W; 3R: V306M, R375W] were P301L 5P-AACAC-GTCCTGG-
GAGGCG-3P, R406W (or R375W) 5P-GGGACACGTCTCCATGG-
CATCTCAGCAAT-3P, V337M (or V306M) 5P-CAGGAGGTGGC-
CA-GATGGAAGTAAAA-3P. DNA was isolated from mutant and
wild type clones and the tau cDNA subcloned in frame into the ex-
pression vector pET30a+ (Novagene) containing either full length 4R,
+2 +3 or 3R, +2 +3 tau. Based on the location of the P301L muta-
tion, only the four repeat tau construct contains this mutation. Tau
cDNA constructs were sequenced using the Big Dye Terminator Cycle
Sequencing kit (Perkin Elmer). Sequencing was performed on an
ABI377 automated sequencer with Sequence Navigator software (Per-
kin Elmer).
2.3. Expression and puri¢cation of recombinant tau
Recombinant tau proteins were expressed in Escherichia coli and
puri¢ed from bacterial lysates as described previously [13,21]. Tau
separated by CM Sepharose chromatography were subjected to
HPLC chromatography (C18 column, 1U25 cm, Vydac), and eluted
with a gradient of 20^50% acetonitrile containing 0.1% tri£uoroacetic
acid in 60 min at a £ow rate of 2 ml/min. The eluates were monitored
at UV 260 Wm. The purity of tau sample was examined by gel electro-
phoresis, followed by Coomassie blue staining and immunoblotting.
Protein content was determined by the bicinchoninic acid method
(Pierce).
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2.4. Digestion of tau with calpain I
Tau proteins (100 Wg/ml) were incubated with porcine erythrocyte
calpain I (EC 3.4.22.17, MW 112 000) at an enzyme:substrate ratio
(based on molarity) of 1:100 (Calbiochem, La Jolla, CA). The reac-
tion mixture contained 20 mM Tris-HCl, pH 7.5, 5 mM L-mercapto-
ethanol, 150 mM NaCl and 100 WM CaCl2. Aliquots of the samples
were removed at various time intervals and mixed immediately with a
6Usample bu¡er containing 12% SDS and 12% L-mercaptoethanol to
terminate the digestion. The samples were boiled and used for gel
electrophoresis and immunoblotting.
2.5. Electrophoresis and blotting
Aliquots of the calpain I digested samples, each containing 1 Wg of
tau, were loaded on 12.5% or 15% SDS-polyacrylamide gels and gel
electrophoresis was performed as described. Proteins separated on gel
were stained with Coomassie brilliant blue or silver stain (Bio-Rad,
Hercules, CA). For immunoblotting, the protein loading was 0.3 Wg.
The separated proteins were electrotransferred to nitrocellulose paper,
and the papers were incubated with 5% non-fat milk in Tris bu¡ered
saline to block non-speci¢c binding, followed by incubation with anti-
tau antibodies. The bound immunoglobulin was detected by enhanced
chemiluminescent system (Amersham, Buckinghamshire). The amount
of undegraded tau was quantitated by the MCID system (Imaging
Research Inc., Ontario).
3. Results and discussions
3.1. Kinetics of tau degradation
3.1.1. Four repeat tau. Wild type and three mutated forms
(P301L, V337M, R406W) of tau containing four tandem re-
peats in the microtubule binding domain and amino-terminal
inserts encoded by exons 2 and 3 were used. These proteins
[4R, +2 +3] were puri¢ed from lysates of bacteria expressing
the tau cDNAs. The proteins were incubated for up to 32 min
at 30‡C with calpain I, a calcium dependent protease. Small
aliquots of the mixtures were removed after 0, 1, 2, 4, 8, 16
and 32 min of incubation and mixed immediately with a
6Usample bu¡er containing SDS to terminate the digestion.
Fig. 1. Degradation of full length four repeat and three repeat tau by calpain I. Undegraded tau and tau incubated with calpain for 1, 2, 4, 8,
16 and 32 min (not shown) were separated by SDS-gel electrophoresis using gels containing 15% polyacrylamide. A and C: Coomassie blue
stained gel, demonstrating the decrease of the amount of intact tau with incubation. The decrease was accompanied by the appearance of mul-
tiple fragments with molecular weight greater than 35 kDa. Low molecular weight regions of the gel (6 35 kDa) were barely stained by the
dye. R406W and V337M mutants were degraded more slowly than P301L mutant or wild type tau. B and D: Kinetics of tau degradation. Er-
ror bars represent standard error of the mean.
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The samples were then subjected to SDS-polyacrylamide gel
electrophoresis and Western blotting with a series of antibod-
ies speci¢c to di¡erent subregions of the tau molecule. The
gels were subjected to Coomassie blue and silver staining, and
analyzed by densitometric scanning using the MCID imaging
system (Imaging Research Inc.). The immunoblots were vis-
ualized with an enzyme-linked chemiluminescent kit (Amer-
sham).
Densitometric analyses of Coomassie blue stained gel re-
vealed that prior to calpain digestion, at least 98% of the
tau was intact (Fig. 1A, 0 min). Unlike wild type tau, mutant
tau displayed a slower rate of degradation (Fig. 1B). On aver-
age, about 8% of the intact wild type tau remained unde-
graded after 16 min of proteolytic digestion. In comparison,
22^32% of mutant tau remained intact with the same duration
of incubation. Most of the degraded fragments (with wild type
or mutant tau) were either too small to be retained in the gel
system used in present studies, stained poorly with Coomassie
blue, or the quantity was below the sensitivity of detection by
the dye. About 50% of the intact wild type tau was degraded
after 1.3 min of incubation. In comparison it took 1.8, 2.2 and
3.6 min to achieve the same degree of degradation of P301L,
V337M and R406W, respectively. The rate of degradation
di¡erences observed between the wild type and V337M or
between the wild type and R406W were statistically signi¢cant
at all time points (P6 0.05; Student’s t-test, n = 8). The di¡er-
ences between the wild type and P301L mutant were signi¢-
cant only for those samples with 8 min or longer incubation.
3.1.2. Three repeat tau. Similar studies were also carried
out with three repeat wild type tau and tau with mutations at
V306M and R375W, which are sites corresponding to V337M
and R406W in four repeat tau. In contrast to four repeat tau,
there were no signi¢cant di¡erences between three repeat mu-
tant tau and wild type tau in the kinetics of degradation (Fig.
1C,D). The results suggest that the presence of the second
tandem repeat is required for mutations to a¡ect the suscept-
ibility of tau to calpain I degradation. Comparison of wild
type tau containing four repeats with wild type tau containing
three repeats did not reveal signi¢cant di¡erences between
these two isoforms in the rate of degradation. The results
are consistent with those reported previously [22].
3.2. Characterization of degraded fragments
3.2.1. Silver staining. Silver stain was used to examine the
calpain digests of four repeat wild type and the corresponding
R406W mutant tau, focusing on the region of the gel between
the 35 kDa molecular weight marker and the bottom of the
gel. Unlike fragments with a molecular weight higher than 35
kDa, the low molecular fragments were poorly stained by
Coomassie blue (presumably due to low quantities and the
relative insensitivity of the dye). However, multiple silver
stained bands were observed in this region of gels (6 35
kDa) containing either digests of four repeat wild type or
mutant tau (Fig. 2, 4R, +2 +3). Most of the bands were
weakly labeled. Some fragments were also detected in undi-
gested controls, presumably derived from degradation that
occurs during protein preparation. A number of bands de-
tected in digests of both wild type and mutant tau were
stained with di¡erent intensities. These were located around
the 30 kDa and between the 20 and 7 kDa regions. A prom-
inent band with molecular weight V10 kDa was detected in
digests of wild type tau (marked by *). This band was less
apparent in the digests of R406W mutant tau, especially those
obtained with shorter incubation periods (compare 2 min ver-
sus 16 min samples). A similar low molecular weight (V10
kDa) fragments was also observed after silver staining gels of
calpain digested three repeat tau (Fig. 2, 3R, +2 +3, marked
by *). In contrast to four repeat tau the intensity of the band
and the incubation time required to generate detectable levels
of the fragment were comparable in the three repeat wild type
and R375W mutant tau.
3.2.2. Immunolabelling. To determine the site of calpain I
cleavage in other regions of the tau molecule, we used anti-
bodies E2, WKS44, Tau-1, E9 and WKS45 to probe 2 min
calpain digests of wild type and mutant tau. These antibodies
recognize epitopes located at amino acid residues 44^55, 162^
176, 192^199, 226^240 and 258^266, respectively (Fig. 3B).
Numerous fragments were detected in the digests. Based on
their immunoreactivities, the fragments could be categorized
into at least seven groups (Fig. 3A). The approximate size of
di¡erent groups and the region of tau susceptible for calpain I
cleavage is illustrated in Fig. 3B,C. Group 1 represents frag-
ments larger than 35 kDa that displayed immunoreactivities
with all tau antibodies tested and are only slightly smaller
than intact tau. These fragments are likely missing either the
amino- and/or the carboxy-end of tau. They may be missing
part of the Tau46 epitopes, since they displayed weaker Tau46
immunoreactivity than that expected according to their immu-
nolabeling with WKS46. Group 2 also represents large frag-
ments but these lack the carboxy-terminus encompassing the
Tau46 epitope. Group 3 includes several fragments missing
the carboxy-terminus encompassing both the Tau46 and the
WKS46 epitopes. Group 4 includes fragments of size approx-
imately 35 kDa. The fragments were mostly weakly labeled by
E1, WKS44, E9 and Tau-1 (data not shown), and not labeled
Fig. 2. Silver staining of low molecular weight regions of gels (6 35
kDa) containing calpain I degraded wild type tau, R406W and
R375W mutant tau. Degraded R406W mutant di¡ered from de-
graded four repeat wild type tau in the incubation time required to
generate small fragments (marked by *), which migrate between the
7.2 kDa and 20 kDa molecular weight markers. They also di¡ered
in the labeling intensity of large sized fragments (between 20 and 29
kDa, or 29 and 35 kDa molecular weight markers). Less di¡erence
was detected between the three repeat wild type and R375W mutant
tau.
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by WKS45, WKS46 or Tau46. Groups 5, 6, and 7 were car-
boxy-terminal fragments containing both the WKS46 and
Tau46 epitopes. Group 5, in addition, contained the WKS45
epitope. Because fragments belonging to group 6 were de-
tected mainly in four repeat tau, they were likely generated
by cleavage of sites within the second repeat. The group 5
fragments were likely generated by cleavage between the E9
and WKS45 epitopes. Group 7 includes low molecular weight
fragments generated by calpain I digestion of wild type and
R406W tau displayed immunoreactivity with antibodies
WKS46 and Tau 46, which recognize epitopes located at the
carboxy end (amino acids 358^370 and 420^436 respectively)
of tau (Fig. 3A,B). The fragments were not recognized by E1,
an antibody that recognizes the amino-end (amino acids 19^
33) of tau (Fig. 3A), or other anti-tau antibodies tested. The
low molecular weight (V10 kDa) fragment identi¢ed by silver
stain belongs to group 7. The results suggest that R406W
mutation leads to a decrease in the accessibility of the car-
boxy-end of tau to calpain I digestion. Since the size of the
low molecular weight fragment is V10 kDa, and the smallest
carboxy-terminal region of tau encompassing both the Tau46
and WKS46 epitopes contains about 83 amino acids (Fig. 3),
the cleavage site a¡ected by the R406W mutation is probably
near the WKS46 epitope, which is 21^33 amino acids down-
stream of V337M and 36^48 amino acids upstream of
R406W.
Control samples (marked with 3) contained small amounts
of endogenously degraded tau, most of which was present as
large (s 35 kDa) fragments. Some of these control fragments
co-migrate with tau fragments obtained after calpain I diges-
tion.
The data obtained from our studies suggest that (1) wild
type and mutant tau are digested by calpain I at similar sites,
(2) many of the cleavage sites are located in the carboxy-ter-
minal half of tau, and (3) the mutation linked decreases in
digestion rate observed in four repeat tau may be due to a
Fig. 3. A: Immunoblotting of calpain degraded tau with antibodies speci¢c to di¡erent subregions of the tau molecule. Controls (3) and sam-
ples digested for 2 min (+) were compared. Degraded fragments were categorized into at least seven groups (marked 1^7) based on their immu-
noreactivities. Molecular weight markers were 7.2, 20, 29, 35, 50 and 83 kDa in size. Lower molecular weight fragments (5^7) reacted mainly
with antibodies speci¢c to epitopes located at the carboxy-end of tau. B: The location of the epitope recognized by di¡erent antibodies. The
approximate sizes of di¡erent groups of fragments generated from digestion of (B) four repeat and (C) three repeat tau are indicated, and the
regions that are likely to contain calpain cleavage sites are marked (b^b). Whether or not the ¢rst or the last 30 amino acids (indicated by dot-
ted lines) are cleaved remains uncertain. aa: amino acids, Ab: antibody.
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reduced accessibility of calpain I to some of the cleavage sites.
How mutations a¡ect protease accessibility remains unclear.
It is possible that this is due to changes in tau conformation.
In this regard, it is noteworthy that in studies of transfected
cultured cells the phosphorylation of four repeat tau was de-
creased by the R406W mutation, but not by the V337M or
P301L mutations [23,24]. Tau proteins with FTDP-17 muta-
tions were also reported in one study to be di¡erent from wild
type tau in circular dichroic (CD) spectra [25]. However, a
subsequent study by others showed that the CD spectra of
wild type and mutant tau were comparable [14]. Standard
physical analyses may be too insensitive to detect subtle
changes of tau structure. For example, standard physical anal-
yses did not reveal any signi¢cant changes in the structure of
insoluble pathologic tau derived from Alzheimer’s disease
(AD) and tau from control brains, but immunization of AD
pathologic tau has led to the production of antibodies that
recognize ‘AD speci¢c’ conformational tau epitopes [25^27].
Further studies undoubtedly are required to de¢ne the e¡ect
of FTDP-17 missense mutation on tau conformation.
The results of the present studies of tau degradation togeth-
er with those of tau ¢lament assembly and microtubule bind-
ing demonstrate that FTDP-17 mutations have at least three
e¡ects on tau in vitro. They also show that the mutations
a¡ect the calpain I degradation of four repeat tau more
than three repeat tau. Reduction in the rate of tau degrada-
tion could lead to increases in the concentration of cytoplas-
mic tau. This in turn could contribute to increased tau poly-
merization into ¢laments. In discussing the multiple e¡ect of
FTDP-17 mutations on tau biology, it is worth noting that
while the R406W mutation has the most prominent e¡ects on
tau degradation, it has an inhibitory e¡ect on the nucleation
process of tau ¢lament polymerization. In contrast, the P301L
mutation has little e¡ect on tau degradation, but increases the
ability of tau to form ¢brils at both nucleation and elongation
phases. Further studies are needed to determine the critical
tau concentration necessary for the initiation of ¢lament for-
mation in vivo.
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